UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number,
including area code): (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered |
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 22, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 1,252,975 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), were present by valid proxy, representing approximately 57.83% of the Company’s outstanding voting power as of the April 24, 2023 record date. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, each of which were described in the Company’s definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2023.
Proposal 1 - Election of five (5) directors to hold office until the Company’s annual meeting of stockholders to be held in 2024 and until his or her respective successor is duly elected and qualified.
| NOMINEE | Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | ||||
| Tomer Kariv | 557,994 | 5,140 | 42,001 | 647,840 | ||||
| Sumit Aggarwal | 511,136 | 4,776 | 89,223 | 647,840 | ||||
| Lindsay Androski, JD, MBA | 559,991 | 3,197 | 41,947 | 647,840 | ||||
| Steven Rubin | 509,103 | 7,248 | 88,784 | 647,840 | ||||
| Alan Walts, Ph.D. | 559,951 | 3,312 | 41,872 | 647,840 |
Proposal 2 - Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.
| Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | |||
| 1,181,736 | 23,057 | 48,182 | 0 |
Proposal 3 - Advisory vote on the compensation of the Company’s named executive officers.
| Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes | |||
| 550,254 | 12,373 | 42,508 | 647,840 |
Based on the foregoing votes, each of the director nominees was elected, and Proposals 2 and 3 were approved.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 23, 2023 | ELOXX PHARMACEUTICALS, INC. | |
| By: |
/s/ Sumit Aggarwal | |
| Name: | Sumit Aggarwal | |
| Title: | President and Chief Executive Officer | |